Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Inhibrx Biosciences Inc's Business Segments
Inhibrx Biosciences Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
License, Non-Affiliate
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- License, Non-Affiliate0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License, Non-Affiliate | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- License, Non-Affiliate0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License, Non-Affiliate | - | - |
Description of Inhibrx Biosciences Inc
Inhibrx Inc. is a biotechnology company focusing on the discovery and development of novel drugs for the treatment of serious diseases. Headquartered in La Jolla, California, Inhibrx utilizes its proprietary protein engineering platform called SDCTM (Single Domain Antibody Complex) to create next-generation therapeutics with enhanced selectivity and efficacy.
The company was founded in 2010 by Mark Lappe, Sara Horton, and to date has grown to employ a team of highly skilled scientists, engineers, and professionals dedicated to advancing innovative treatments. Inhibrx has built a strong patent portfolio around its SDCTM technology, providing a solid foundation for its drug discovery efforts.
Inhibrx excels in developing novel therapeutics targeting various diseases, including cancer, autoimmune disorders, and infectious diseases. Its SDCTM platform enables the generation of fully human monoclonal antibodies, which have shown great potential in selectively targeting disease-specific proteins. By leveraging the power of its technology, Inhibrx has successfully developed a robust pipeline of potential drug candidates.
The company's research and development activities encompass various stages of drug development, including target identification, lead discovery, preclinical development, and clinical trials. Inhibrx's multidisciplinary approach involves collaboration with academic institutions, pharmaceutical companies, and clinical investigators to accelerate the translation of its discoveries into effective therapeutics.
Inhibrx's commitment to advancing healthcare is evident in its comprehensive clinical development program. The company has initiated multiple clinical trials to evaluate the safety and efficacy of its drug candidates. These trials aim to demonstrate the potential of Inhibrx's innovative therapies in providing meaningful clinical benefits to patients.
In addition to its drug development efforts, Inhibrx also emphasizes manufacturing excellence. The company has established state-of-the-art manufacturing facilities to support the production of its investigational drugs, ensuring their quality, safety, and scalability.
Moreover, Inhibrx maintains strong collaborations with other biotechnology and pharmaceutical companies, enabling it to access additional resources and expertise. These partnerships are crucial for expanding the therapeutic potential of Inhibrx's technologies and fostering the development of breakthrough treatments.
Overall, Inhibrx Inc. is a cutting-edge biotechnology company at the forefront of the development of novel therapeutics. Its innovative SDCTM platform, strong patent portfolio, and dedication to advancing healthcare make it well-positioned to address unmet medical needs and make a significant impact on patients' lives.
The company was founded in 2010 by Mark Lappe, Sara Horton, and to date has grown to employ a team of highly skilled scientists, engineers, and professionals dedicated to advancing innovative treatments. Inhibrx has built a strong patent portfolio around its SDCTM technology, providing a solid foundation for its drug discovery efforts.
Inhibrx excels in developing novel therapeutics targeting various diseases, including cancer, autoimmune disorders, and infectious diseases. Its SDCTM platform enables the generation of fully human monoclonal antibodies, which have shown great potential in selectively targeting disease-specific proteins. By leveraging the power of its technology, Inhibrx has successfully developed a robust pipeline of potential drug candidates.
The company's research and development activities encompass various stages of drug development, including target identification, lead discovery, preclinical development, and clinical trials. Inhibrx's multidisciplinary approach involves collaboration with academic institutions, pharmaceutical companies, and clinical investigators to accelerate the translation of its discoveries into effective therapeutics.
Inhibrx's commitment to advancing healthcare is evident in its comprehensive clinical development program. The company has initiated multiple clinical trials to evaluate the safety and efficacy of its drug candidates. These trials aim to demonstrate the potential of Inhibrx's innovative therapies in providing meaningful clinical benefits to patients.
In addition to its drug development efforts, Inhibrx also emphasizes manufacturing excellence. The company has established state-of-the-art manufacturing facilities to support the production of its investigational drugs, ensuring their quality, safety, and scalability.
Moreover, Inhibrx maintains strong collaborations with other biotechnology and pharmaceutical companies, enabling it to access additional resources and expertise. These partnerships are crucial for expanding the therapeutic potential of Inhibrx's technologies and fostering the development of breakthrough treatments.
Overall, Inhibrx Inc. is a cutting-edge biotechnology company at the forefront of the development of novel therapeutics. Its innovative SDCTM platform, strong patent portfolio, and dedication to advancing healthcare make it well-positioned to address unmet medical needs and make a significant impact on patients' lives.
Inhibrx Biosciences Inc is committed to advancing biopharmaceutical drugs through extensive research and development, focusing on innovative therapies for serious medical conditions. Their operations can be categorized into several segments, products, and services, each integral to their mission of addressing unmet medical needs.
Segments:
1. Oncology:
Inhibrx is heavily engaged in oncology research, concentrating on the development of novel cancer therapies. The approach involves identifying specific tumor targets, which allows the creation of highly selective monoclonal antibody therapeutics aimed at various cancers. By focusing on personalized treatment strategies, Inhibrx aims to offer solutions for different tumor types and stages, leading to improved patient outcomes.
2. Immunology:
The immunology segment addresses a range of disorders, including autoimmune diseases and chronic inflammatory conditions. Inhibrxs goal in this sector is to develop therapies that not only alleviate symptoms but also target underlying disease mechanisms. This effort aims to enhance patient quality of life, particularly for those battling long-term immunological challenges.
3. Infectious Diseases:
In the realm of infectious diseases, Inhibrx pursues the development of therapeutics for a variety of pathogens, including bacteria and viruses. The company focuses on generating effective treatment options that respond to the challenges of emerging and evolving infectious agents. Their research includes exploring unique pathways and responses that pathogens exploit, allowing them to create more effective interventions.
Products:
1. Monoclonal Antibodies (mAbs):
A cornerstone of Inhibrxs product portfolio, their monoclonal antibodies are designed to target specific biomarkers or antigens found on cancer cells or infected individuals. The precision of these therapies aims to minimize harm to healthy tissues while effectively eradicating pathogenic or malignant cells.
2. Fusion Proteins:
Inhibrx develops fusion proteins that integrate the therapeutic benefits of multiple agents into a single entity. These proteins typically consist of a monoclonal antibody fragment joined with additional therapeutic modules, creating a multi-modal approach that can tackle diseases from different angles, thus enhancing treatment efficacy.
3. Bispecific Antibodies:
Innovatively designed to bind to two different antigens simultaneously, Inhibrx’s bispecific antibodies facilitate the redirection of immune responses, allowing immune cells to engage directly with tumor cells or deliver specific therapeutic agents to targeted cells. This strategic approach aims to amplify the therapeutic impact and improve treatment outcomes for patients.
Services:
1. Preclinical Development:
Inhibrx offers comprehensive preclinical development services, including in vitro and in vivo pharmacological studies. These studies are crucial for assessing the safety, efficacy, and mechanism of action of their drug candidates prior to entering clinical trials. By establishing a solid foundation in preclinical results, Inhibrx improves the likelihood of clinical success.
2. Clinical Development:
The company undertakes various phases of clinical trials to evaluate the safety and efficacy of their investigational drugs in human subjects. This includes phase I trials, which focus on safety, through to later phases that assess the therapeutic effectiveness in targeted patient populations. Their structured approach to clinical development is designed to meet regulatory requirements while also providing critical data for healthcare decision-making.
3. Manufacturing and Supply Chain Management:
Inhibrx leverages its expertise in biologics manufacturing to ensure high-quality production of its therapeutics. The company manages all aspects of the supply chain to guarantee timely distribution of its products to healthcare providers and patients, facilitating access to cutting-edge therapies.
Conclusion:
Inhibrx Biosciences Inc stands at the forefront of biopharmaceutical innovation, developing a diverse range of segments, products, and services. Their concentrated efforts in oncology, immunology, and infectious diseases translate into a robust pipeline of novel therapeutics aimed at effectively addressing serious health issues, demonstrating their commitment to improving patient care and outcomes through significant scientific advancement.
Segments:
1. Oncology:
Inhibrx is heavily engaged in oncology research, concentrating on the development of novel cancer therapies. The approach involves identifying specific tumor targets, which allows the creation of highly selective monoclonal antibody therapeutics aimed at various cancers. By focusing on personalized treatment strategies, Inhibrx aims to offer solutions for different tumor types and stages, leading to improved patient outcomes.
2. Immunology:
The immunology segment addresses a range of disorders, including autoimmune diseases and chronic inflammatory conditions. Inhibrxs goal in this sector is to develop therapies that not only alleviate symptoms but also target underlying disease mechanisms. This effort aims to enhance patient quality of life, particularly for those battling long-term immunological challenges.
3. Infectious Diseases:
In the realm of infectious diseases, Inhibrx pursues the development of therapeutics for a variety of pathogens, including bacteria and viruses. The company focuses on generating effective treatment options that respond to the challenges of emerging and evolving infectious agents. Their research includes exploring unique pathways and responses that pathogens exploit, allowing them to create more effective interventions.
Products:
1. Monoclonal Antibodies (mAbs):
A cornerstone of Inhibrxs product portfolio, their monoclonal antibodies are designed to target specific biomarkers or antigens found on cancer cells or infected individuals. The precision of these therapies aims to minimize harm to healthy tissues while effectively eradicating pathogenic or malignant cells.
2. Fusion Proteins:
Inhibrx develops fusion proteins that integrate the therapeutic benefits of multiple agents into a single entity. These proteins typically consist of a monoclonal antibody fragment joined with additional therapeutic modules, creating a multi-modal approach that can tackle diseases from different angles, thus enhancing treatment efficacy.
3. Bispecific Antibodies:
Innovatively designed to bind to two different antigens simultaneously, Inhibrx’s bispecific antibodies facilitate the redirection of immune responses, allowing immune cells to engage directly with tumor cells or deliver specific therapeutic agents to targeted cells. This strategic approach aims to amplify the therapeutic impact and improve treatment outcomes for patients.
Services:
1. Preclinical Development:
Inhibrx offers comprehensive preclinical development services, including in vitro and in vivo pharmacological studies. These studies are crucial for assessing the safety, efficacy, and mechanism of action of their drug candidates prior to entering clinical trials. By establishing a solid foundation in preclinical results, Inhibrx improves the likelihood of clinical success.
2. Clinical Development:
The company undertakes various phases of clinical trials to evaluate the safety and efficacy of their investigational drugs in human subjects. This includes phase I trials, which focus on safety, through to later phases that assess the therapeutic effectiveness in targeted patient populations. Their structured approach to clinical development is designed to meet regulatory requirements while also providing critical data for healthcare decision-making.
3. Manufacturing and Supply Chain Management:
Inhibrx leverages its expertise in biologics manufacturing to ensure high-quality production of its therapeutics. The company manages all aspects of the supply chain to guarantee timely distribution of its products to healthcare providers and patients, facilitating access to cutting-edge therapies.
Conclusion:
Inhibrx Biosciences Inc stands at the forefront of biopharmaceutical innovation, developing a diverse range of segments, products, and services. Their concentrated efforts in oncology, immunology, and infectious diseases translate into a robust pipeline of novel therapeutics aimed at effectively addressing serious health issues, demonstrating their commitment to improving patient care and outcomes through significant scientific advancement.